侵袭性真菌病（IFD）是危及生命的疾病，需要及时和适当治疗。研究表明，伊沙曲唑治疗对临床结局和住院时间（LOS）有积极影响。本研究的目的是使用德国一家癌症中心的真实世界数据评估被诊断为IFD并接受伊沙曲唑治疗的患者的医院费用。检索了科隆大学医院内科I部门于2016年1月至2021年6月收集的数据和LOS。通过采用卫生保健付款者的角度，确定了使用口服、静脉注射和混合给药途径的伊沙曲唑治疗期间耗用的与病例相关的资源，并进行了量化、估值和比较的成本分析。总共识别了101例接受伊沙曲唑治疗的病例（口服：n = 22，21.8％；静脉注射：n = 59，58.4％；混合：n = 20，19.8％）。混合组的中位总LOS更长（46.5天；p = .009）。静脉注射组的ICU中位LOS和通气持续时间都最长（16天，p = .008; 224小时，p = .003）。侵袭性曲霉病是最常见的伊沙曲唑适应症（n = 86，85.2％）。混合组的平均医院费用最高（101,226欧元）。接受伊沙曲唑治疗的病例的中位总费用为52,050欧元。治疗IFD需要大量资源，通常需要重症监护和高死亡率。我们的研究强调了高的医院治疗成本，因此需要报销系统来实现救生性昂贵治疗。 ©2023TheAuthors。Wiley-VCH GmbH发表的真菌病。

Invasive fungal diseases (IFD) are life-threatening and demand timely and appropriate treatment. Research showed that isavuconazole treatment positively affects clinical outcome and length of hospital stay (LOS).The aim of this study was to assess the hospital costs of patients diagnosed with IFD and treated with isavuconazole using real-world data from a German cancer centre.Data and LOS collected from Jan-2016 to Jun-2021 at Department I of Internal Medicine, University Hospital Cologne were retrieved. Case-related resources consumed during the hospital stay across isavuconazole routes of administration (oral, parenteral, and mixed administration) were identified, quantified, valued and compared via a cost analysis that adopted the healthcare payer perspective.In total, 101 cases with isavuconazole treatment were identified (oral: n = 22, 21.8%; parenteral: n = 59, 58.4%; mixed: n = 20, 19.8%). Median total LOS was greater in the mixed group (46.5 days; p = .009). Median ICU LOS and ventilation duration were both longest in the parenteral-only group (16 days, p = .008; 224 h, p = .003). Invasive aspergillosis was the most frequent isavuconazole indication (n = 86, 85.2%). Average hospital costs were highest in the mixed group (€ 101,226). The median overall costs of cases treated with isavuconazole was € 52,050.Treating IFD is resource intensive, often requires intensive care and implies high rates of in-hospital mortality. Our study emphasises the high hospital treatment costs and thus the need for reimbursement systems to enable live-saving costly treatments.© 2023 The Authors. Mycoses published by Wiley-VCH GmbH.